Skip to content
HCC Buddy home

C92.51 ICD-10-CM Code: Acute myelomonocytic leukemia, in remission

C92.51 maps to CMS-HCC V28 17. A source-labeled RAF reference is available. Documentation must support MEAT. MEAT criteria · RAF Calculator · HCC coding software

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)

C92.51

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Acute myelomonocytic leukemia, in remission

A type of blood cancer (acute myelomonocytic leukemia) where the cancer cells have responded to treatment and are no longer detectable.

Buddy the Bee presenting code insight

Buddy Insight

Acute myelomonocytic leukemia in remission indicates successful response to induction chemotherapy with resolution of the dual myeloid/monocytic proliferation and normalization of bone marrow.

CMS-HCC V28

HCC 17

Code-level coefficient reference

CMS-HCC V24

Historical

Historical

Not used for CY2026 payment

ACA/HHS

HCC 008

Code-level coefficient reference

ESRD/PACE

HCC 8

Code-level coefficient reference

RXHCC

HCC 19

Code-level coefficient reference

Code Book Path

Official
C92Myeloid leukemia
C92.5Acute myelomonocytic leukemia
C92.51Acute myelomonocytic leukemia, in remission

Inclusion Terms

Official
  • AML M4
  • AML M4 Eo with inv(16) or t(16;16)

Excludes 2

Official

ICD-10-CM does not list Excludes 2 notes for C92.51 in this effective period.

Related Child Codes

Official
C92.50Acute myelomonocytic leukemia, not having achieved remission
C92.52Acute myelomonocytic leukemia, in relapse

Includes

Official

ICD-10-CM does not list Includes notes for C92.51 in this effective period.

Excludes 1

Official

ICD-10-CM does not list Excludes 1 notes for C92.51 in this effective period.

Code First

Official

ICD-10-CM does not list Code First sequencing instructions for C92.51 in this effective period.

Use Additional

Official

ICD-10-CM does not list Use Additional Code instructions for C92.51 in this effective period.

Code Also

Official

ICD-10-CM does not list Code Also instructions for C92.51 in this effective period.

Buddy Documentation Tip

HCC Buddy guidance
Documentation must confirm remission with bone marrow blasts less than 5%, resolution of monocytic component, and count recovery.
The cytogenetic subtype (particularly inv(16) status) should remain documented as it influences consolidation therapy decisions.
Minimal residual disease assessment, consolidation treatment plan, and transplant candidacy evaluation should be recorded.

MEAT Support

HCC Buddy guidance
Documentation must confirm remission with bone marrow blasts less than 5%, resolution of monocytic component, and count recovery.
The cytogenetic subtype (particularly inv(16) status) should remain documented as it influences consolidation therapy decisions.
Minimal residual disease assessment, consolidation treatment plan, and transplant candidacy evaluation should be recorded.

Audit Caution

HCC Buddy guidance
Verify complete resolution of both myeloid and monocytic abnormal populations in the bone marrow. Post-remission extramedullary disease (skin, gingiva) must also be resolved to claim remission. Do not assume remission based on peripheral blood count normalization alone -
bone marrow assessment is required. Patients with the M4Eo variant in remission have excellent prognoses with appropriate consolidation.

Common Mistakes

HCC Buddy guidance
C92.50 (AMML not in remission) is for active disease.
C92.52 (AMML in relapse) is for recurrent disease.
C93.01 (acute monoblastic/monocytic leukemia in remission) is for purely monocytic leukemia.
C92.01 (AML in remission) is a less specific alternative.

Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →

Is C92.51 an HCC code?

Yes. C92.51 (Acute myelomonocytic leukemia, in remission) maps to HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 4.209. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.

Coder answer: C92.51 is billable and maps to V28 HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.

Code
C92.51
Description
Acute myelomonocytic leukemia, in remission
HCC (V28)
HCC 17 — Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic
RAF reference coefficient
4.209
Billable
Yes
Payment year
2026

HCC Category Mapping

V28HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic
4.209
ESRDHCC 8, Metastatic Cancer and Acute Leukemia
Not separately weighted
RxHCCHCC 19, Leukemias and Other Hematologic Cancers
Not separately weighted

These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.

Work C92.51 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →

MEAT Criteria for C92.51

For C92.51 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.

  • MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
  • EEvaluate: test results, medication response, or physical findings reviewed by the provider
  • AAssess: explicit mention in the assessment or plan with acknowledgment of status
  • TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C92.51 during that encounter, not just copy-forwarded from a problem list.

Coder workflow notes

Get the V28 mapping + MEAT cheat sheet

One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.

Free PDF. No card. Unsubscribe anytime.

What This Code Means

C92.51 is the ICD-10-CM diagnosis code for acute myelomonocytic leukemia, in remission. A type of blood cancer (acute myelomonocytic leukemia) where the cancer cells have responded to treatment and are no longer detectable. C92.51 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).

Under the CMS-HCC V28 risk adjustment model, C92.51 maps to Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic (HCC 17) with a source-labeled community, non-dual, aged reference coefficient of 4.209. No V24 mapping is shown for C92.51; use the applicable model and payment year when reviewing the V28 mapping. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.

Use this code only when documentation explicitly states the patient is in remission. Because C92.51 maps to an HCC category, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) before the diagnosis is used for risk adjustment. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for C92.51 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

  • •Use this code only when documentation explicitly states the patient is in remission
  • •Remission status must be clearly documented in the medical record; do not assume based on treatment alone

Clinical Significance

Acute myelomonocytic leukemia in remission indicates successful response to induction chemotherapy with resolution of the dual myeloid/monocytic proliferation and normalization of bone marrow. The M4Eo variant with inv(16) has particularly good remission rates and long-term outcomes. Post-remission consolidation therapy, including potential high-dose cytarabine cycles, is essential to reduce relapse risk.

Documentation Requirements

  • ✓Documentation must confirm remission with bone marrow blasts less than 5%, resolution of monocytic component, and count recovery.
  • ✓The cytogenetic subtype (particularly inv(16) status) should remain documented as it influences consolidation therapy decisions.
  • ✓Minimal residual disease assessment, consolidation treatment plan, and transplant candidacy evaluation should be recorded.

Commonly Confused Codes

  • •C92.50 (AMML not in remission) is for active disease.
  • •C92.52 (AMML in relapse) is for recurrent disease.
  • •C93.01 (acute monoblastic/monocytic leukemia in remission) is for purely monocytic leukemia.
  • •C92.01 (AML in remission) is a less specific alternative.
  • •Z85.6 (personal history of leukemia) should not be used during active post-remission treatment.

Child Codes

C92.50Acute myelomonocytic leukemia, not having achieved remission
HCC 17
C92.51Acute myelomonocytic leukemia, in remission
HCC 17
C92.52Acute myelomonocytic leukemia, in relapse
HCC 17

Code Hierarchy

└C92Myeloid leukemia└C92.5Acute myelomonocytic leukemia└C92.51Acute myelomonocytic leukemia, in remission
└C92.51Acute myelomonocytic leukemia, in remission

Because C92.51 maps to an HCC category, the documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) before the diagnosis is used for risk adjustment.

C92.51 maps to CMS-HCC V28 category 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic. See the ICD-10 to HCC mapping hub for how the V28 crosswalk works. The mapping identifies a payment HCC category for C92.51. Review its source-labeled HCC coefficient above, check the RAF Calculator with complete member context for CMS-HCC V28 PY2026, and confirm the documentation the chart needs before the code is submitted. HCC Buddy shows no RAF score unless every required source and calculation check passes.

Work C92.51 in HCC Buddy

Open C92.51 in the Code Book for the full Index-to-Tabular path, MEAT checklist, and V28 HCC mapping, or in the Encoder to code from a keyword search. Pro includes 7 days to try everything, no card required.

Open in Code BookOpen in EncoderStart Pro